Prudential Financial
CYCN icon

Prudential Financial’s Cyclerion Therapeutics CYCN Stock Holding History

Prudential Financial’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,614
Closed -$29K – 2665
2022
Q2 		$29K Buy
+2,614
New +$37.4K ﹤0.01% 2622
2019
Q4 		– Sell
-1,006
Closed -$244K – 2440
2019
Q3 		$244K Sell
1,006
-879
-47% -$190K ﹤0.01% 2262
2019
Q2 		$432K Buy
+1,885
New +$533K ﹤0.01% 2134

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TFS
TrustCore Financial Services Brentwood, Tennessee $1.14B AUM 13.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return

Prudential Financial's CYCN Position: Q3 2022 in Review

Prudential Financial sold out of Cyclerion Therapeutics (CYCN) in Q3 2022, closing a stake of 2,614 shares — an estimated $29K sold.

Prudential Financial first reported a position in CYCN in Q2 2019 and held it in 3 quarters. The position peaked at $432K in Q2 2019. 37 funds tracked by Wall St. Rank hold CYCN as of Q3 2022.

  • Prudential Financial reported no remaining Cyclerion Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Prudential Financial sold 2,614 Cyclerion Therapeutics shares in Q3 2022, an estimated $29K.
  • Prudential Financial first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 3 quarters.
  • Prudential Financial's Cyclerion Therapeutics position peaked at $432K in Q2 2019.
  • 37 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q3 2022.

Based on Prudential Financial's 13F filing for Q3 2022, filed 4 Nov 2022.